Activity of BAL 4815 against filamentous fungi

Aller, Ana Isabel; López-Oviedo, E.; Romero, A.; Martos, A. I.; Cantón, Emilia; Pemán, Javier; Martos, P. García; Martín-Mazuelos, Estrella

doi:10.1093/jac/dkn076

Cited by 22 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isavuconazole demonstrated potent in vitro activity against Aspergillus sp. (15, 24) and limited antifungal activity against zygomycetes (15,24,30,37). In comparison to the results with itraconazole, ravuconazole, and voriconazole, isavuconazole showed potent activity against zygomycetes, especially against Rhizopus species (15,30,37).…”

Section: Discussionmentioning

confidence: 97%

Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern

et al. 2010

View full text Add to dashboard Cite

Apophysomyces elegans is an emerging pathogen in India. We planned the present study to analyze the clinical pattern of the disease, to perform molecular strain typing, and to determine the in vitro activities of eight antifungal drugs against A. elegans. A total of 16 clinical and two environmental A. elegans isolates were included in the study. The clinical histories of the patients were noted. MICs or minimum effective concentrations (MECs) were determined for antifungal drugs by microdilution testing in accordance with CLSI standard M38-A2 guidelines. Of 16 patients, seven had rhino-cerebral, five had cutaneous, and three had renal zygomycosis. One patient had osteomyelitis. Uncontrolled diabetes was observed in 63% of the patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern

et al. 2010

View full text Add to dashboard Cite

show abstract

“…This compound demonstrated in vitro activity and in vivo efficacy against a broad range of yeasts and molds, including Aspergillus spp., Fusarium spp., Candida spp., the Mucorales, Cryptococcus spp., and black yeasts and their filamentous relatives (25,(55)(56)(57)(58)(59)(60)(61)(62)(63).…”

Section: Discussionmentioning

confidence: 99%

Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model

Seyedmousavi

Brüggemann

Meis

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…In studies using Clinical and Laboratory Standards Institute (CLSI) methodology, the MIC50 and MIC90 for the two most common Aspergillus species, A. fumigatus and A. flavus, ranged 0.5-2 µg/mL and 1-2 µg/mL for A. fumigatus and 0.5-2 µg/mL and 1-4 µg/mL for A. flavus (Table 2). [37][38][39][40] Higher minimum inhibitory concentration (MIC) values have consistently been observed with A. niger. 37,38,40,41 When obtained by using the methodology set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the MIC50 and MIC90 of isavuconazole against Aspergillus species appear similar.…”

Section: In Vitro Activity Against Aspergillus Speciesmentioning

confidence: 99%

“…[37][38][39][40] Higher minimum inhibitory concentration (MIC) values have consistently been observed with A. niger. 37,38,40,41 When obtained by using the methodology set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the MIC50 and MIC90 of isavuconazole against Aspergillus species appear similar. 39,42,43 The clinical significance of MIC variability according to Aspergillus species is not yet clear.…”

Section: In Vitro Activity Against Aspergillus Speciesmentioning

confidence: 99%

Orphan drugs for the treatment of aspergillosis: focus on isavuconazole

Jacobs¹,

Petraitis²,

Small³

et al. 2017

ODRR

View full text Add to dashboard Cite

Invasive aspergillosis (IA) is a particularly devastating manifestation of Aspergillus infection affecting profoundly immunocompromised patients. Voriconazole has been approved as first-line therapy for IA since 2003; however, nonlinear pharmacokinetics, adverse effects, and drug-drug interactions at time hinder its use. Isavuconazole is a new broad-spectrum triazole with potent activity against Aspergillus species. In animal models and clinical trials in humans, isavuconazole has shown comparable efficacy to that of voriconazole in the treatment of IA. Advantages of isavuconazole include a more favorable pharmacokinetic profile and fewer adverse events. This review summarizes the pharmacologic characteristics, in vitro activity, and clinical data supporting the use of isavuconazole as an emerging alternative therapy for IA.

show abstract

Activity of BAL 4815 against filamentous fungi

Abstract: BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi.

Cited by 22 publications

References 11 publications

Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern

Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern

Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model

Orphan drugs for the treatment of aspergillosis: focus on isavuconazole

Contact Info

Product

Resources

About